Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Accumulated Depreciation (2016 - 2023)

Historic Accumulated Depreciation for Editas Medicine (EDIT) over the last 9 years, with Q2 2023 value amounting to $23.5 million.

  • Editas Medicine's Accumulated Depreciation rose 2638.26% to $23.5 million in Q2 2023 from the same period last year, while for Jun 2023 it was $23.5 million, marking a year-over-year increase of 2638.26%. This contributed to the annual value of $21.5 million for FY2022, which is 3881.47% up from last year.
  • As of Q2 2023, Editas Medicine's Accumulated Depreciation stood at $23.5 million, which was up 2638.26% from $22.0 million recorded in Q1 2023.
  • Editas Medicine's Accumulated Depreciation's 5-year high stood at $23.5 million during Q2 2023, with a 5-year trough of $5.1 million in Q1 2019.
  • Over the past 5 years, Editas Medicine's median Accumulated Depreciation value was $12.6 million (recorded in 2021), while the average stood at $13.3 million.
  • In the last 5 years, Editas Medicine's Accumulated Depreciation surged by 99.54% in 2019 and then skyrocketed by 5640.02% in 2020.
  • Quarter analysis of 5 years shows Editas Medicine's Accumulated Depreciation stood at $7.2 million in 2019, then skyrocketed by 54.01% to $11.1 million in 2020, then skyrocketed by 39.77% to $15.5 million in 2021, then skyrocketed by 38.81% to $21.5 million in 2022, then increased by 9.13% to $23.5 million in 2023.
  • Its last three reported values are $23.5 million in Q2 2023, $22.0 million for Q1 2023, and $21.5 million during Q4 2022.